JP6082463B2 - 第ｘｉａ因子阻害剤としてのジヒドロピリドンｐ１ - Google Patents
第ｘｉａ因子阻害剤としてのジヒドロピリドンｐ１ Download PDFInfo
- Publication number
- JP6082463B2 JP6082463B2 JP2015525622A JP2015525622A JP6082463B2 JP 6082463 B2 JP6082463 B2 JP 6082463B2 JP 2015525622 A JP2015525622 A JP 2015525622A JP 2015525622 A JP2015525622 A JP 2015525622A JP 6082463 B2 JP6082463 B2 JP 6082463B2
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- methyl
- nonadeca
- tetrahydropyridin
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc1nnc(*)[o]1 Chemical compound Cc1nnc(*)[o]1 0.000 description 6
- ZEFGUWRQFNTGGX-UHFFFAOYSA-N C1NN=CC=C1 Chemical compound C1NN=CC=C1 ZEFGUWRQFNTGGX-UHFFFAOYSA-N 0.000 description 1
- FSPIBFKGESGOLU-UHFFFAOYSA-N CC(C=C(C)N1)=CC1=O Chemical compound CC(C=C(C)N1)=CC1=O FSPIBFKGESGOLU-UHFFFAOYSA-N 0.000 description 1
- NTRPAMBLEXVPQJ-BELJIYFPSA-N CC(CCC1)CC1C(CCN1[C@@H](CCC[C@@H](C)C(Nc2c-3ccc(NC(OC)=O)c2)=O)c2cc-3ccn2)=CC1=O Chemical compound CC(CCC1)CC1C(CCN1[C@@H](CCC[C@@H](C)C(Nc2c-3ccc(NC(OC)=O)c2)=O)c2cc-3ccn2)=CC1=O NTRPAMBLEXVPQJ-BELJIYFPSA-N 0.000 description 1
- FHTHEOCGYPFYBM-GMTBNIFVSA-N CC(CCC[C@@H](c1cc(-c(c(F)c(cc2)F)c2N2)ccn1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound CC(CCC[C@@H](c1cc(-c(c(F)c(cc2)F)c2N2)ccn1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2=O FHTHEOCGYPFYBM-GMTBNIFVSA-N 0.000 description 1
- JORBAAKNOUMANA-KKFPZRRJSA-N CC(CCC[C@@H](c1cc(-c(cc2)c3cc2NC(OC)=O)ccn1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)NC3=O Chemical compound CC(CCC[C@@H](c1cc(-c(cc2)c3cc2NC(OC)=O)ccn1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)NC3=O JORBAAKNOUMANA-KKFPZRRJSA-N 0.000 description 1
- BKSCSZWESYMLPD-KKFPZRRJSA-N CC(CCC[C@@H](c1nccc(-c(ccc(C#N)c2)c2N2)c1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound CC(CCC[C@@H](c1nccc(-c(ccc(C#N)c2)c2N2)c1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2=O BKSCSZWESYMLPD-KKFPZRRJSA-N 0.000 description 1
- DFGOMBKDJQTHJN-SCSAIBSYSA-N C[C@H](C=C)C(Cl)=O Chemical compound C[C@H](C=C)C(Cl)=O DFGOMBKDJQTHJN-SCSAIBSYSA-N 0.000 description 1
- CZVFTXBLLAZNNP-DFXYEROKSA-N C[C@H](CCCC[C@@H](c1nccc(-c(cccc2)c2N2)c1)N(CCC(c(cc(cc1)Cl)c1-[n]1ncnc1)=C1)C1=O)C2=O Chemical compound C[C@H](CCCC[C@@H](c1nccc(-c(cccc2)c2N2)c1)N(CCC(c(cc(cc1)Cl)c1-[n]1ncnc1)=C1)C1=O)C2=O CZVFTXBLLAZNNP-DFXYEROKSA-N 0.000 description 1
- XHXHYSLQUPGOGY-CPJLOUKISA-N C[C@H](CCC[C@@H](c1cc(-c(ccc(NC(OC)=O)c2)c2N2)ccn1)N(CC(c(c(Br)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1cc(-c(ccc(NC(OC)=O)c2)c2N2)ccn1)N(CC(c(c(Br)ccc1Cl)c1F)=C1)C1=O)C2=O XHXHYSLQUPGOGY-CPJLOUKISA-N 0.000 description 1
- IMCXJEIDVWMIBG-QUGAMOGWSA-N C[C@H](CCC[C@@H](c1cc(-c(ccc(NC(OC)=O)c2)c2N2)ccn1)N(CCC(c(c(F)ccc1Br)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1cc(-c(ccc(NC(OC)=O)c2)c2N2)ccn1)N(CCC(c(c(F)ccc1Br)c1F)=C1)C1=O)C2=O IMCXJEIDVWMIBG-QUGAMOGWSA-N 0.000 description 1
- SEYYELZSACSHCW-GDJIYFAZSA-N C[C@H](CCC[C@@H](c1cc(-c(ccc(Nc2ncccn2)c2)c2N2)ccn1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1cc(-c(ccc(Nc2ncccn2)c2)c2N2)ccn1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2=O SEYYELZSACSHCW-GDJIYFAZSA-N 0.000 description 1
- QCLXOYCQRRMTLX-KEEVHDRGSA-N C[C@H](CCC[C@@H](c1cc(-c(cccc2)c2N2)ccn1)N(CCC(c(c(C(C)=O)ccc1C3=CC3)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1cc(-c(cccc2)c2N2)ccn1)N(CCC(c(c(C(C)=O)ccc1C3=CC3)c1F)=C1)C1=O)C2=O QCLXOYCQRRMTLX-KEEVHDRGSA-N 0.000 description 1
- YPAISRDCVKHFMI-CLYVBNDRSA-N C[C@H](CCC[C@@H](c1cccc(-c(ccc(NC(OC)=O)c2)c2N2)c1)N(CCC(c(c(Br)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1cccc(-c(ccc(NC(OC)=O)c2)c2N2)c1)N(CCC(c(c(Br)ccc1Cl)c1F)=C1)C1=O)C2=O YPAISRDCVKHFMI-CLYVBNDRSA-N 0.000 description 1
- TXRMRQKQNYNOAW-CMJOXMDJSA-N C[C@H](CCC[C@@H](c1nccc(-c(c(F)c(cc2)F)c2N2)c1)N(CCC(c(c(Br)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(c(F)c(cc2)F)c2N2)c1)N(CCC(c(c(Br)ccc1Cl)c1F)=C1)C1=O)C2=O TXRMRQKQNYNOAW-CMJOXMDJSA-N 0.000 description 1
- ZPJLQXFNQCVGJK-CPJLOUKISA-N C[C@H](CCC[C@@H](c1nccc(-c(c(F)cc(F)c2)c2N2)c1)N(C=CC(c(cccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(c(F)cc(F)c2)c2N2)c1)N(C=CC(c(cccc1Cl)c1F)=C1)C1=O)C2=O ZPJLQXFNQCVGJK-CPJLOUKISA-N 0.000 description 1
- COBYDNLRERTJSP-WRHNGFHOSA-N C[C@H](CCC[C@@H](c1nccc(-c(cc(C)c(O)c2C)c2N2)c1)N(CCC(c(c(F)ccc1C3=CC3)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(cc(C)c(O)c2C)c2N2)c1)N(CCC(c(c(F)ccc1C3=CC3)c1F)=C1)C1=O)C2=O COBYDNLRERTJSP-WRHNGFHOSA-N 0.000 description 1
- BNZCCWRWIPSVFG-DWXRJYCRSA-N C[C@H](CCC[C@@H](c1nccc(-c(cc(C)cc2)c2N2)c1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(cc(C)cc2)c2N2)c1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2=O BNZCCWRWIPSVFG-DWXRJYCRSA-N 0.000 description 1
- OBSGJFCIYCQJEU-CPJLOUKISA-N C[C@H](CCC[C@@H](c1nccc(-c(cc(cc2)F)c2N2)c1)N(CCC(c(c(Br)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(cc(cc2)F)c2N2)c1)N(CCC(c(c(Br)ccc1Cl)c1F)=C1)C1=O)C2=O OBSGJFCIYCQJEU-CPJLOUKISA-N 0.000 description 1
- HXEKGJHLQWBYKJ-CPJLOUKISA-N C[C@H](CCC[C@@H](c1nccc(-c(ccc(NC(OC)=O)c2)c2N2)c1)N1N=CC(c(c(F)ccc3Cl)c3F)=CC1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(ccc(NC(OC)=O)c2)c2N2)c1)N1N=CC(c(c(F)ccc3Cl)c3F)=CC1=O)C2=O HXEKGJHLQWBYKJ-CPJLOUKISA-N 0.000 description 1
- HXSGPPWCKSNISI-CLYVBNDRSA-N C[C@H](CCC[C@@H](c1nccc(-c(ccc(Nc2nnc(CC#N)[o]2)c2)c2N2)c1)N(CCC(C(C(F)=C(CC1)Cl)=C1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(ccc(Nc2nnc(CC#N)[o]2)c2)c2N2)c1)N(CCC(C(C(F)=C(CC1)Cl)=C1F)=C1)C1=O)C2=O HXSGPPWCKSNISI-CLYVBNDRSA-N 0.000 description 1
- IRQQHHGYQUYTOU-OLILMLBXSA-N C[C@H](CCC[C@@H](c1nccc(-c(cccc2)c2N2)c1)N(CCC(c(c(-c1c[n](C)nc1)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(cccc2)c2N2)c1)N(CCC(c(c(-c1c[n](C)nc1)ccc1Cl)c1F)=C1)C1=O)C2=O IRQQHHGYQUYTOU-OLILMLBXSA-N 0.000 description 1
- CMVGISXWABZZHF-KEEVHDRGSA-N C[C@H](CCC[C@@H](c1nccc(-c(cccc2)c2N2)c1)N(CCC(c(c(-c1c[n](C)nc1C)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(cccc2)c2N2)c1)N(CCC(c(c(-c1c[n](C)nc1C)ccc1Cl)c1F)=C1)C1=O)C2=O CMVGISXWABZZHF-KEEVHDRGSA-N 0.000 description 1
- TWJJMUHZMNPHFS-SZNDQCEHSA-N C[C@H](CCC[C@@H](c1nccc(-c(cn[nH]2)c2N2)c1)N(CCC(c(c(F)c(cc1)Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@@H](c1nccc(-c(cn[nH]2)c2N2)c1)N(CCC(c(c(F)c(cc1)Cl)c1F)=C1)C1=O)C2=O TWJJMUHZMNPHFS-SZNDQCEHSA-N 0.000 description 1
- BSNSKODJGQKGRG-DNOBIOAJSA-N C[C@H](CCC[C@H](c1cc(-c(cc(cc2)C(OC)=O)c2N2)ccc1)N(CCC(c(c(Br)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@H](c1cc(-c(cc(cc2)C(OC)=O)c2N2)ccc1)N(CCC(c(c(Br)ccc1Cl)c1F)=C1)C1=O)C2=O BSNSKODJGQKGRG-DNOBIOAJSA-N 0.000 description 1
- PQMIPRJGMKRLRT-DNOBIOAJSA-N C[C@H](CCC[C@H](c1cccc(-c(cc(cc2)C(OC)=O)c2N2)c1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2=O Chemical compound C[C@H](CCC[C@H](c1cccc(-c(cc(cc2)C(OC)=O)c2N2)c1)N(CCC(c(c(F)ccc1Cl)c1F)=C1)C1=O)C2=O PQMIPRJGMKRLRT-DNOBIOAJSA-N 0.000 description 1
- IVKBDJJDCIBYDW-HCCKASOXSA-N Cc1c(C)cc2N[C@H](C3)C3c2c1 Chemical compound Cc1c(C)cc2N[C@H](C3)C3c2c1 IVKBDJJDCIBYDW-HCCKASOXSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N Cc1ccccn1 Chemical compound Cc1ccccn1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N c1cncnc1 Chemical compound c1cncnc1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N c1nccnc1 Chemical compound c1nccnc1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679197P | 2012-08-03 | 2012-08-03 | |
| US61/679,197 | 2012-08-03 | ||
| US201361787081P | 2013-03-15 | 2013-03-15 | |
| US61/787,081 | 2013-03-15 | ||
| PCT/US2013/053416 WO2014022767A1 (en) | 2012-08-03 | 2013-08-02 | Dihydropyridone p1 as factor xia inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015528022A JP2015528022A (ja) | 2015-09-24 |
| JP2015528022A5 JP2015528022A5 (enExample) | 2016-04-14 |
| JP6082463B2 true JP6082463B2 (ja) | 2017-02-15 |
Family
ID=48949290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015525622A Active JP6082463B2 (ja) | 2012-08-03 | 2013-08-02 | 第ｘｉａ因子阻害剤としてのジヒドロピリドンｐ１ |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9409908B2 (enExample) |
| EP (1) | EP2880026B1 (enExample) |
| JP (1) | JP6082463B2 (enExample) |
| KR (1) | KR20150038372A (enExample) |
| CN (2) | CN108250199B (enExample) |
| AR (1) | AR091981A1 (enExample) |
| AU (1) | AU2013296259A1 (enExample) |
| BR (1) | BR112015002081A2 (enExample) |
| CA (1) | CA2880866A1 (enExample) |
| CY (1) | CY1119004T1 (enExample) |
| DK (1) | DK2880026T3 (enExample) |
| EA (1) | EA028581B1 (enExample) |
| ES (1) | ES2623175T3 (enExample) |
| HR (1) | HRP20170506T1 (enExample) |
| HU (1) | HUE032622T2 (enExample) |
| IL (1) | IL237011A0 (enExample) |
| LT (1) | LT2880026T (enExample) |
| MX (1) | MX361759B (enExample) |
| PL (1) | PL2880026T3 (enExample) |
| PT (1) | PT2880026T (enExample) |
| RS (1) | RS55975B1 (enExample) |
| SG (1) | SG11201500271UA (enExample) |
| SI (1) | SI2880026T1 (enExample) |
| SM (1) | SMT201700240T1 (enExample) |
| TW (1) | TW201410667A (enExample) |
| UY (1) | UY34960A (enExample) |
| WO (1) | WO2014022767A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021088610A (ja) * | 2014-01-31 | 2021-06-10 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| JP6033317B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| UY34393A (es) | 2011-10-14 | 2013-04-30 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia |
| US9403774B2 (en) | 2012-10-12 | 2016-08-02 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EA032092B1 (ru) | 2012-10-12 | 2019-04-30 | Бристол-Майерс Сквибб Компани | Кристаллические формы ингибитора фактора xia |
| EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| FR3010076B1 (fr) * | 2013-09-02 | 2016-12-23 | Centre Nat De La Rech Scient - Cnrs - | Inhibiteurs de metalloproteases, leurs procedes de preparation et leurs utilisations therapeutiques |
| NO2760821T3 (enExample) | 2014-01-31 | 2018-03-10 | ||
| CN107074821B (zh) | 2014-09-04 | 2020-05-22 | 百时美施贵宝公司 | 为fxia抑制剂的二酰胺大环化合物 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (enExample) * | 2014-10-01 | 2018-10-20 | ||
| CN108026083B (zh) * | 2015-06-19 | 2021-08-27 | 百时美施贵宝公司 | 作为因子xia抑制剂的二酰胺大环 |
| JO3703B1 (ar) * | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| EP3868753B1 (en) * | 2015-07-29 | 2022-12-21 | Bristol-Myers Squibb Company | Factor xia macrocyclic inhibitors bearing a non-aromatic p2' group |
| JP6629958B2 (ja) * | 2015-07-29 | 2020-01-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アルキルまたはシクロアルキルＰ２’基を担持する大員環の第ＸＩａ因子阻害剤 |
| KR102697816B1 (ko) * | 2015-08-05 | 2024-08-21 | 브리스톨-마이어스 스큅 컴퍼니 | 신규 치환된 글리신 유도된 fxia 억제제 |
| MA43128A (fr) * | 2015-10-29 | 2018-09-05 | Merck Sharp & Dohme | Inhibiteurs du facteur xia |
| EP3371162B1 (en) | 2015-10-29 | 2022-01-26 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use |
| US10752641B2 (en) | 2016-03-02 | 2020-08-25 | Bristol-Myers Squibb Company | Diamide macrocycles having factor XIa inhibiting activity |
| US10143681B2 (en) | 2016-08-22 | 2018-12-04 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| WO2018133793A1 (zh) * | 2017-01-18 | 2018-07-26 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
| WO2019011166A1 (zh) * | 2017-07-14 | 2019-01-17 | 四川科伦博泰生物医药股份有限公司 | 大环酰胺化合物及其药物组合物和用途 |
| AU2020257911B2 (en) | 2019-04-16 | 2023-01-05 | China Resources Biopharmaceutical Company Limited | Macrocyclic derivatives acting as XIa factor inhibitor |
| US20220281868A1 (en) * | 2019-07-23 | 2022-09-08 | Medshine Discovery Inc. | Macrocyclic derivatives as factor xia inhibitors |
| CN113004284B (zh) * | 2019-12-20 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为血浆激肽释放酶抑制剂的四环类化合物及其用途 |
| WO2021121396A1 (zh) * | 2019-12-20 | 2021-06-24 | 成都康弘药业集团股份有限公司 | 作为血浆激肽释放酶抑制剂的三环类化合物及其用途 |
| US20230312560A1 (en) * | 2020-07-22 | 2023-10-05 | Janssen Pharmaceutica Nv | Compounds useful as factor xia inhibitors |
| CN119894901A (zh) * | 2023-06-30 | 2025-04-25 | 深圳信立泰药业股份有限公司 | 一种多取代的大环化合物及其制备方法与应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| AU5546000A (en) | 1999-06-14 | 2001-01-02 | Protherics Molecular Design Limited | Compounds |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| HRP20080382A2 (en) | 2001-09-21 | 2008-12-31 | Bristol-Myers Squibb Company A Delaware (Usa) Corporation | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| CN101137412B (zh) | 2005-01-13 | 2012-11-07 | 布里斯托尔-迈尔斯·斯奎布公司 | 用作凝血因子XIa抑制剂的取代的二芳基化合物 |
| WO2006089005A2 (en) | 2005-02-17 | 2006-08-24 | Bristol-Myers Squibb Company | Combination of selective factor viia and/or xia and plasma kallikrein inhibitors |
| US8466295B2 (en) | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
| US8163749B2 (en) | 2005-12-14 | 2012-04-24 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| NZ568595A (en) | 2005-12-14 | 2010-04-30 | Bristol Myers Squibb Co | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors |
| US8410155B2 (en) | 2006-12-15 | 2013-04-02 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors |
| PE20081775A1 (es) * | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
| MX2009012847A (es) | 2007-06-13 | 2009-12-08 | Bristol Myers Squibb Co | Analogos dipeptidicos como inhibidores de factores de coagulacion. |
| ATE543811T1 (de) | 2008-03-13 | 2012-02-15 | Bristol Myers Squibb Co | Pyridazinderivate als faktor-xia-inhibitoren |
| KR101843542B1 (ko) * | 2010-02-11 | 2018-03-30 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 ＸＩａ 억제제로서의 마크로사이클 |
| TW201311689A (zh) * | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| UY34393A (es) | 2011-10-14 | 2013-04-30 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| JP6033317B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| ES2765891T3 (es) | 2011-12-21 | 2020-06-11 | Ono Pharmaceutical Co | Derivados de piridinona y pirimidinona como inhibidores del factor XIa |
| JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| GB201209138D0 (en) | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
-
2013
- 2013-08-02 BR BR112015002081A patent/BR112015002081A2/pt active Search and Examination
- 2013-08-02 JP JP2015525622A patent/JP6082463B2/ja active Active
- 2013-08-02 SI SI201330570A patent/SI2880026T1/sl unknown
- 2013-08-02 DK DK13747625.5T patent/DK2880026T3/en active
- 2013-08-02 AR ARP130102764A patent/AR091981A1/es unknown
- 2013-08-02 MX MX2015000892A patent/MX361759B/es active IP Right Grant
- 2013-08-02 WO PCT/US2013/053416 patent/WO2014022767A1/en not_active Ceased
- 2013-08-02 KR KR1020157004963A patent/KR20150038372A/ko not_active Withdrawn
- 2013-08-02 ES ES13747625.5T patent/ES2623175T3/es active Active
- 2013-08-02 CN CN201810051705.4A patent/CN108250199B/zh active Active
- 2013-08-02 AU AU2013296259A patent/AU2013296259A1/en not_active Abandoned
- 2013-08-02 SM SM20170240T patent/SMT201700240T1/it unknown
- 2013-08-02 TW TW102127905A patent/TW201410667A/zh unknown
- 2013-08-02 US US14/419,002 patent/US9409908B2/en active Active
- 2013-08-02 PT PT137476255T patent/PT2880026T/pt unknown
- 2013-08-02 UY UY0001034960A patent/UY34960A/es unknown
- 2013-08-02 RS RS20170501A patent/RS55975B1/sr unknown
- 2013-08-02 CA CA2880866A patent/CA2880866A1/en not_active Abandoned
- 2013-08-02 HR HRP20170506TT patent/HRP20170506T1/hr unknown
- 2013-08-02 EA EA201590277A patent/EA028581B1/ru not_active IP Right Cessation
- 2013-08-02 LT LTEP13747625.5T patent/LT2880026T/lt unknown
- 2013-08-02 SG SG11201500271UA patent/SG11201500271UA/en unknown
- 2013-08-02 CN CN201380040942.6A patent/CN104507924B/zh active Active
- 2013-08-02 EP EP13747625.5A patent/EP2880026B1/en active Active
- 2013-08-02 HU HUE13747625A patent/HUE032622T2/en unknown
- 2013-08-02 PL PL13747625T patent/PL2880026T3/pl unknown
-
2015
- 2015-01-29 IL IL237011A patent/IL237011A0/en unknown
-
2016
- 2016-07-08 US US15/205,059 patent/US9951071B2/en active Active
-
2017
- 2017-05-09 CY CY20171100499T patent/CY1119004T1/el unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021088610A (ja) * | 2014-01-31 | 2021-06-10 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP7325464B2 (ja) | 2014-01-31 | 2023-08-14 | ブリストル－マイヤーズ スクイブ カンパニー | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| JP2023133468A (ja) * | 2014-01-31 | 2023-09-22 | ブリストル－マイヤーズ スクイブ カンパニー | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6082463B2 (ja) | 第ｘｉａ因子阻害剤としてのジヒドロピリドンｐ１ | |
| JP6630004B2 (ja) | 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 | |
| JP6419836B2 (ja) | ヘテロサイクルと縮合した大環状第ｘｉａ因子阻害剤 | |
| JP6462865B2 (ja) | 第ｘｉａ因子阻害剤としてのピリミジノン | |
| JP5537442B2 (ja) | 第ｘｉａ因子阻害剤としてのピリダジン誘導体 | |
| JP6479763B2 (ja) | 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン | |
| JP6082462B2 (ja) | 第ｘｉａ因子阻害剤としてのジヒドロピリドンｐ１ | |
| JP2018525368A (ja) | アルキルまたはシクロアルキルＰ２’基を担持する大員環の第ＸＩａ因子阻害剤 | |
| JP6816103B2 (ja) | 非芳香族性Ｐ２’基を担持する新規大員環の第ＸＩａ因子阻害剤 | |
| HK40053570A (en) | Pyrimidinones as factor xia inhibitors | |
| HK40053570B (en) | Pyrimidinones as factor xia inhibitors | |
| HK1227032A1 (en) | Pyrimidinones as factor xia inhibitors | |
| HK1227032B (en) | Pyrimidinones as factor xia inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20160219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160224 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160224 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160913 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160915 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161212 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170117 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170120 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6082463 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |